Last Updated: September 23, 2026

Meitheal Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for MEITHEAL

MEITHEAL has eighty-two approved drugs.

There are three US patents protecting MEITHEAL drugs.

Summary for Meitheal

US Patents:	3
Tradenames:	69
Ingredients:	68
NDAs:	82

Drugs and US Patents for Meitheal

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Meitheal	CYTARABINE	cytarabine	INJECTABLE;INJECTION	208485-001	Feb 28, 2022	AP	RX	No	No		⤷ Start Trial				⤷ Start Trial
Meitheal	MICAFUNGIN SODIUM	micafungin sodium	INJECTABLE;INTRAVENOUS	215381-002	Sep 28, 2022	AP	RX	No	No		⤷ Start Trial				⤷ Start Trial
Meitheal	OCTREOTIDE ACETATE	octreotide acetate	INJECTABLE;INJECTION	075957-001	Oct 3, 2005	AP	RX	No	No		⤷ Start Trial				⤷ Start Trial
Meitheal	LEVOLEUCOVORIN CALCIUM	levoleucovorin calcium	POWDER;INTRAVENOUS	211003-001	Aug 22, 2019		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Meitheal	PEMETREXED DISODIUM	pemetrexed disodium	POWDER;INTRAVENOUS	215479-002	Dec 13, 2022	AP	RX	No	No		⤷ Start Trial				⤷ Start Trial
Meitheal	CONTEPO	fosfomycin disodium	POWDER;INTRAVENOUS	212271-001	Oct 22, 2025		RX	Yes	Yes	10,086,006	⤷ Start Trial				⤷ Start Trial
Meitheal	CYTARABINE	cytarabine	INJECTABLE;INJECTION	206190-001	Nov 9, 2017		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Paragraph IV (Patent) Challenges for MEITHEAL drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	250 mcg/0.5 mL, 1 mL PFS	➤ Subscribe	2012-03-30

International Patents for Meitheal Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Korea	20200069262	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2018222656	⤷ Start Trial
Australia	2018277757	⤷ Start Trial
New Zealand	759953	⤷ Start Trial
South Africa	201908325	⤷ Start Trial
South Korea	102597622	⤷ Start Trial
Israel	271045	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Meitheal Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0430190	SPC/GB05/032	United Kingdom	⤷ Start Trial	PRODUCT NAME: PALONOSETRON OR AN ISOMER, MIXTURE OF ISOMERS, N-OXIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/306/001 20050322
3300601	301185	Netherlands	⤷ Start Trial	PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
2701720	CA 2022 00054	Denmark	⤷ Start Trial	PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
1189916	SZ 2/2011	Austria	⤷ Start Trial	PRODUCT NAME: REGADENOSON UND DESSEN SALZE
0321122	SPC/GB96/057	United Kingdom	⤷ Start Trial	PRODUCT NAME: TOPOTECAN; REGISTERED: CH IKS-NR:53857 19961016; UK EU/1/96/027/001 19961112; UK EU/1/96/027/002 19961112
1744764	C201830057	Spain	⤷ Start Trial	PRODUCT NAME: DAUNORUBICINA + CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823
2371361	122019000082	Germany	⤷ Start Trial	PRODUCT NAME: PLERIXAFOR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER EIN PHARMAZEUTISCH ANNEHMBARER METALLKOMPLEX DAVON; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Meitheal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.